Skip to main content

Clinuvel Pharmaceuticals Value Stock - Dividend - Research Selection

Clinuvel pharmaceuticals


Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company\'s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited was incorporated in 1999 and is headquartered in Melbourne, Australia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Afamelanotide in fair-skinned Parkinson’s patients

Preclinical models show benefit of afamelanotide as MC1R therapy in Parkinson’s DiseaseMELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through melanocortin-1 receptor (MC1R) activation – is able to lower α-synuclein (a toxin) in blood levels in PD patients,

Institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV) shares but retail investors control 59% of the company

Key Insights The considerable ownership by retail investors in Clinuvel Pharmaceuticals indicates that they...

Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Clinuvel Pharmaceuticals' (ASX:CUV) stock is up by a considerable 8.7% over the past month. Since the market usually...